CTMX — CytomX Therapeutics, Inc.

Is CTMX overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Neutral As of October 3, 2026

CytomX Therapeutics, Inc. (CTMX) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Biotechnology) last closed at $2.56. The rating moved from Oversold to Neutral on October 1, 2026.

AI analysis

CytomX Therapeutics, Inc. is a clinical‑stage biotech with a differentiated Probody platform and partnership history that supports technology validation. Near‑term valuation will be driven primarily by upcoming clinical readouts and any partnership/milestone announcements, while cash runway and potential need for financing remain key operational considerations.

Key factors

  • Probody platform and differentiated bispecific/ADC approach that can create targeted therapeutics with potentially improved safety profiles
  • Late‑stage biologics and rare‑disease positive sentiment in the sector could provide constructive comparators and selective investor interest for successful readouts
  • Existing partnerships and licensing history that validate platform potential and can provide non‑dilutive funding or milestone upside
  • Clinical catalysts (upcoming trial readouts or regulatory milestones) represent the primary near‑term value drivers
  • Macro risk‑off environment and reduced biotech funding/IPO appetite are limiting near‑term liquidity and investor appetite for clinical‑stage names
  • Policy and payer pressures (Medicare negotiation themes) increase uncertainty around pricing and commercial economics for novel, high‑cost therapies

Risks

  • High clinical execution risk: pivotal or late‑stage readout failures or safety signals would materially depress valuation
  • Cash runway and dilution risk given ongoing R&D burn; need for financing could lead to share issuance at depressed prices
  • Policy and payer pressure (Medicare negotiation/IRA) that could reduce pricing power or access for novel therapeutics
  • Competitive threats from established biologics, bispecifics, ADCs and alternative modalities that could crowd target indications or compress pricing
  • Market liquidity and sentiment sensitivity: risk‑off environment could amplify downside on negative news and mute upside on positive data
  • Regulatory delays or additional data requests that extend timelines and increase development costs

See today's live rating, score and targets

Members see the live hourly rating for CTMX — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.